Cell Impact Q2 2023: Temporary lower level of activity and cost reduction program
Cell Impact AB (Nasdaq First North GM: CI) reports the following summary for the second quarter 2023.Net sales during the second quarter totaled SEK 17.2 million (20.4). The operating profit, which dropped to –27.1 MSEK (–21.8), is disappointing and contrary to previously expected development. Before the second quarter, we saw indications of significantly increased demand during the second half-year and we expected a good full year. Instead, we received indications that involve delays in orders. Against this backdrop, in July, we announced a cost reduction program to adapt our